Clinical trial · Interventional
Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients
Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy \& Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment. Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tissue Biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Study group
- interventionNames
- Diagnostic Test: Tissue Biopsy
- type
- NO_INTERVENTION
- label
- Excluded Patients
Primary outcomes (1)
- measure
- expression levels of p53/L1CAM/ER/PR
- timeFrame
- 36 Months
- description
- The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 36 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: * aged 36 -72 years; * Previously diagnosed with endometrial carcinoma; * Histological Type of the tumor; * Myometrial Invasion; * lymph Node Invasion; * Cervical Invasion; * Biomarkers expression. Exclusion Criteria: * Lack of tumor tissue in tissue block
References
Publications (0)
Data not yet available